Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2A study of Radspherin

Next Previous
Trial Profile

Phase 2A study of Radspherin

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Radspherin (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use

Most Recent Events

  • 10 Feb 2023 According to Oncoinvent media release, the company anticipates to publish 15-month and 18-month progression free survival data in the same group of patients at conferences later this year.
  • 10 Feb 2023 According to Oncoinvent media release, inclusion for phase IIA has been initiated.
  • 25 Aug 2022 According to an Oncoinvent media release, the study has been conducted at two sites, the Radium Hospital in Oslo Norway and at the Uppsala University Hospital in Uppsala Sweden.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top